Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging. 

Companies making the news 
Here is a roundup of recent news announcements from DCAT Member Companies across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging.  
 
See related stories and the companies making the news below:   

From DCAT Week 2024: Supplier News: Chemicals/Chemical API Manufacturing
Featuring news from Olon, Grace, PharmaBlock, Axplora, ChemCon, Suven Pharma and The Solubility Company. 

From DCAT Week 2024: Supplier News: Biologics Manufacturing
Featuring news from Siegfried and Solvias. 

From DCAT Week 2024: Supplier News: Formulation Development/Drug Product Manufacturing 
Featuring news from Alcami, Corealis Pharma, Curia, Delpharm and Grand River Aseptic Manufacturing. 

From DCAT Week 2024: Supplier News: End-to-End (Drug Substance and Drug Product)
Featuring news from Lonza and Mabion.  

From DCAT Week 2024: Supplier News: Packaging 
Featuring news from Adare Pharma Solutions and ApiJect 

Recent Feature Articles

The Battle of the Blockbusters: GLP-1 Agonists

By
GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?

Manufacturing & Supply Lines: Small-Molecule APIs

By
Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.